Immunotherapies such as PD-1/PD-L1 blockade using monoclonal antibodies, developed for treating cancers, will not be practical for malaria treatment or activation of host immune response before vaccination, mainly due to high costs and potential immune-related adverse events (irAEs). Here, CD274 is linked to cancer.